Lacosamide

Drugbox
IUPAC_name = (2"R")-2-(acetylamino)-"N"-benzyl-3-methoxypropanamide

---

CAS_number = 175481-36-4
ATC_prefix = N03
ATC_suffix = AX18
PubChem = 219078
DrugBank =
C=13|H=18|N=2|O=3
molecular_weight = 250.294 g/mol
bioavailability = High
protein_bound =
metabolism =
elimination_half-life = 13 hours
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration = Oral, intravenous

Lacosamide (INN, formerly known as erlosamide) is a medication developed by UCB for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain to be marketed under the trade name Vimpat.

The U.S. Food and Drug Administration has accepted UCB's New Drug Application for lacosamide as of November 29, 2007, beginning the approval process for the drug.cite press release | title = UCB Announces FDA Filing for lacosamide in the Treatment of Diabetic Neuropathic Pain | publisher = UCB| date = 2007-11-29 | url = http://www.ucb-group.com/plugins/DirectView.asp?PReleaseID=1171590&NAhead=UCB%20Announces%20FDA%20Filing%20for%20lacosamide%20in%20the%20Treatment%20of%20Diabetic%20Neuropathic%20Pain%20&NAdate=2007-11-29 | accessdate = 2007-11-29 ] [cite press release | title = UCB Announces FDA Filing for lacosamide in the Treatment of Partial Onset Seizures in Adults with Epilepsy | publisher = UCB | date = 2007-11-29 | url = http://www.ucb-group.com/plugins/DirectView.asp?PReleaseID=1171586&NAhead=UCB%20Announces%20FDA%20Filing%20for%20lacosamide%20in%20the%20Treatment%20of%20Partial%20Onset%20Seizures%20in%20Adults%20with%20Epilepsy%20&NAdate=2007-11-29 | accessdate = 2007-11-29 ] UCB has also filed for marketing approval in the European Union; the European Medicines Agency accepted the marketing application for review in May 2007.cite news | url = http://www.nelm.nhs.uk/Record%20Viewing/vR.aspx?id=584410 | title = Marketing application for lacosamide (Vimpat) filed in EU for treatment of diabetic neuropathic pain | last = Wan | first = Yuet | date = August 17 2007 | accessdate = 2007-11-30 | publisher = "PharmaTimes" through the UK National electronic Library for Medicines]

The drug was later approved in the EU on September 3, 2008. [cite press release
title = Vimpat® Approved in Europe
publisher = UCB
date = 2008-09-03
url = http://www.ucb-group.com/news/3606.asp
accessdate = 2008-09-17]

Mechanism of action

Lacosamide is an NMDA receptor antagonist, acting at the receptor's glycine binding site. [ [http://www.prous.com/molecules/default.asp?ID=131 Prous Science: Molecule of the Month January 2005] ]

Clinical trials

In a large double-blind, randomized clinical trial of people with poorly controlled partial-onset seizures, lacosamide was found to significantly reduce seizure frequency when given in addition to other antiepileptics, at doses of 400 and 600 milligrams a day.cite journal |author=Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD |title=Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures |journal=Epilepsia |volume=48 |issue=7 |pages=1308–17 |year=2007 |pmid=17635557 |doi=10.1111/j.1528-1167.2007.01188.x] In a smaller trial of people with diabetic neuropathy, lacosamide also provided significantly better pain relief when compared to placebo.cite journal |author=Rauck RL, Shaibani A, Biton V, Simpson J, Koch B |title=Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study |journal=Clin J Pain |volume=23 |issue=2 |pages=150–8 |year=2007 |pmid=17237664 |doi=10.1097/01.ajp.0000210957.39621.b2]

References